Russia's Gamaleya Institute Completing Phase 2 Trials of Sputnik Light Single-Shot Vaccine

© Sputnik / Sergey Averin / Go to the photo bankA medical worker holds a tube with Russian Gam-COVID-VAK (trademark "Sputnik V") coronavirus vaccine at a Donetsk clinic, the self-proclaimed Donetsk People's Republic, Eastern Ukraine.
A medical worker holds a tube with Russian Gam-COVID-VAK (trademark Sputnik V) coronavirus vaccine at a Donetsk clinic, the self-proclaimed Donetsk People's Republic, Eastern Ukraine.  - Sputnik International, 1920, 12.02.2021
Subscribe
US
India
Global
MOSCOW (Sputnik) - Russia's Gamaleya research institute is completing the second phase of clinical trials of the Sputnik Light vaccine against the coronavirus, institute chief Alexander Gintsburg said on Friday.

Sputnik Light is a single-shot spin-off of the Sputnik V vaccine against COVID-19.

"A month passed since it was first mentioned, and Gamaleya institute managed to conduct the first phase and is currently completing the second phase of the clinical trials," Gintsburg said, as aired by Russia-24 broadcaster.
© Sputnik / Evgeniy Odinokov / Go to the photo bankEvaluation of Sputnik V Vaccine Effectiveness in the Gemotest Laboratory in Moscow, Russia
Russia's Gamaleya Institute Completing Phase 2 Trials of Sputnik Light Single-Shot Vaccine - Sputnik International, 1920, 12.02.2021
Evaluation of Sputnik V Vaccine Effectiveness in the Gemotest Laboratory in Moscow, Russia

Russia's Gamaleya research institute has also developed a technology to quickly develop vaccines against different strains of COVID-19, the director of the institute said.

"Our institute ... has developed a technology that enables very quick and efficient creation of vaccines that include antigens not to just one strain of the coronavirus ... but to two, three, four or five variants," Alexander Gintsburg said, as aired by Russia-24 broadcaster.
Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала